Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition
Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties.